RTY-694 is a potent, orally active ABCB4/BSEP positive functional modulator (PFM) that improves bile composition and enhances bile flow The differentiated mechanism of a dual-targeted ABCB4/BSEP PFM addresses the underlying pathophysiology of cholestasis and cholangitis associated with multiple hepatobiliary diseases, including primary sclerosing cholangitis RTY-694 improved bile composition and demonstrated reductions in bile duct injury, […]

CHICAGO, Oct. 22, 2024 (GLOBE NEWSWIRE) — Uber Freight, the leading end-to-end enterprise suite powering intelligent logistics, today announced a significant milestone in its ongoing efforts to support shippers in Mexico, achieving $750 million in Freight Under Management (FUM). This success underscores the company’s strategic investments and commitment to helping shippers navigate the complexities of

LEXINGTON, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) — KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing novel treatments for solid tumors, today announced the appointment of John Lepore, M.D., to the company’s board of directors. Dr. Lepore brings over 20 years of leadership experience in R&D and drug discovery to KSQ’s board. “As we

Vaudreuil-Dorion, Quebec, Oct. 22, 2024 (GLOBE NEWSWIRE) — Hangcha Forklift Canada (“Hangcha Canada” or “the Company”), a wholly-owned subsidiary of the esteemed Hangcha Group has officially marked five years since its establishment on October 18, 2019. Launched with an initial investment of USD 3 million, Hangcha Canada entered the market aiming to bypass importers and

San Diego, CA, Oct. 22, 2024 (GLOBE NEWSWIRE) — Truepic, the enterprise solution for digital content authenticity, and Inc., the leading media brand and playbook for the entrepreneurs and business leaders shaping our future, announced that Truepic has been recognized as one of Inc.’s Power Partner Best B2B Providers in the Business Products and Services

BOTHELL, Wash., Oct. 22, 2024 (GLOBE NEWSWIRE) — Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that results from the Phase 2/3 LIFT-AD clinical trial of fosgonimeton to treat Alzheimer’s disease (AD) will be presented at the 17th Annual

WALTHAM, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its third quarter 2024 financial results on Tuesday, November 5, 2024, at 8:30 a.m. ET. To access the live call by phone, please pre-register for the call here.

SAN FRANCISCO, Oct. 22, 2024 (GLOBE NEWSWIRE) — WHO: Tenor, providers of AI-driven leadership development solutions that redefine traditional training WHAT: Will present “Leadership Skills in the Age of AI” during the Association for Talent Development (ATD) Leadership Development Day. WHEN: Wednesday, October 30, 2024, from 10:00 a.m. to 4:00 p.m. ET. Tenor’s session will

Approval of SELARSDI 130 mg/26 mL in a single-dose vial for intravenous infusion expands label to include treatment of adults with Crohn’s disease and ulcerative colitis The FDA previously approved SELARSDI 45 mg/0.5 mL and 90 mg/mL in a single-dose prefilled syringe for subcutaneous injection in April 2024 SELARSDI’s U.S. launch for all indications is

London, UK – October 22, 2024 – Quell Therapeutics Ltd (“Quell”), a leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, announces upcoming oral and poster presentations at the 2024 European Society of Gene and Cell Therapy (ESGCT) 31st Annual Congress, held in Rome, Italy (October 22-25,